Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
1. A pharmaceutical composition comprising as an active substance:
a) an isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to a corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein resulting from mutation of the transmembrane (TM) subunit of the corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein,
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is any amino acid,
X a is any amino acid, and X b is A, F, G or R, or
X a is A, F, G, L or R, and X b is A, F, G or R,
or
b) at least one fragment of said isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to the corresponding wild type non-mutated human or simian lentiviral ENV protein,
said fragment comprising at least 40 amino acids,
said fragment comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein,
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is any amino acid,
X a is any amino acid, and X b is A, F, G or R, or
X a is A, F, G, L or R, and X b is A, F, G or R,
in association with a pharmaceutically acceptable carrier,
said no or reduction of immunosuppressive activity of the above mentioned mutated human or simian lentiviral ENV protein or of the above defined fragment being liable to be assessed by the fact that in an in vivo assay involving engrafted tumor cells rejection,
said tumor cells being transduced either so as to express said mutated ENV protein or said fragment (mutated ENV tumor cells),
or said tumor cells being transduced so as to express the corresponding wild type non-mutated ENV protein or a fragment thereof (wild type ENV tumor cells),
or said tumor cells being not transduced (normal tumor cells),
the following ratio:
immunosuppression index of said mutated ENV protein or of said fragment (i mutated env )/immunosuppression index of wild type ENV protein (i wild type env ) is less than 0.5,
i mutated env being defined by: (maximum area reached by mutated ENV tumor cells−maximum area reached by normal tumor cells)/(maximum area reached by normal tumor cells), and
i wild type env being defined by: (maximum area reached by wild type ENV tumor cells−maximum area reached by normal tumor cells)/(maximum area reached by normal tumor cells).
2. The pharmaceutical composition according to claim 1 , comprising as an active substance:
a) an isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to a corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein resulting from mutation of the transmembrane (TM) subunit of the corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is L, I, V, M or P, or
X a is Y, I, H, C or T, and X b is A, F, G or R, or
X a is A, F, G, L or R, and X b is A, F, G or R,
or
b) at least one fragment of said isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to a corresponding wild type non-mutated human or simian lentiviral ENV protein,
said fragment comprising at least 40 amino acids,
said fragment comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is L, I, V, M or P, or
X a is Y, I, H, C or T, and X b is A, F, G or R, or
X a is A, F, G, L or R, and X b is A, F, G or R,
in association with a pharmaceutically acceptable carrier.
3. The pharmaceutical composition according to claim 1 , comprising as an active substance:
a) an isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to a corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein resulting from mutation of the transmembrane (TM) subunit of the corresponding wild type non-mutated human or simian lentiviral ENV protein,
said mutated human or simian lentiviral ENV protein comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is L, or
X a is Y, and X b is A, F, G or R,
or
b) at least one fragment of said isolated mutated human or simian lentiviral ENV protein having no or a reduced immunosuppressive activity as compared to a corresponding wild type non-mutated human or simian lentiviral ENV protein,
said fragment comprising at least 40 amino acids,
said fragment comprising a mutated immunosuppressive domain (ISU) containing the following amino acid sequence:
(SEQ ID NO: 416)
A-[I/V]-E-[K/R]-X a -X b -X-D-Q,
wherein
X represents any amino acid,
and either
X a is A, F, G, L or R, and X b is L, or
X a is Y, and X b is A, F, G or R,
in association with a pharmaceutically acceptable carrier.
4. The pharmaceutical composition according to claim 1 , wherein said isolated mutated human or simian lentiviral ENV protein or said fragment of said isolated mutated human or simian lentiviral ENV protein comprises one of the following amino acid sequences:
(SEQ ID NO: 422)
A-I-E-K-X a -X b -X-DQ,
(SEQ ID NO: 423)
A-I-E-R-X a -X b -X-DQ,
(SEQ ID NO: 424)
A-V-E-K-X a -X b -X-DQ,
(SEQ ID NO: 425)
A-V-E-R-X a -X b -X-DQ.
5. The pharmaceutical composition according to claim 1 , wherein said isolated mutated human or simian lentiviral ENV protein, or said fragment of said isolated mutated human or simian lentiviral ENV protein, comprises one of the amino acid sequences selected from the group consisting of: SEQ ID NO: 13, SEQ ID NO: 42, SEQ ID NO: 71, SEQ ID NO: 9 to 12, SEQ ID NO: 14 to 41, SEQ ID NO: 43 to 70, and SEQ ID NO: 72 to 269.
6. The pharmaceutical composition according to claim 1 , in a formulation for its use for inhibiting lentiviral infection.
7. The pharmaceutical composition according to claim 1 , wherein said isolated mutated human or simian lentiviral ENV protein, or said fragment of said isolated mutated human or simian lentiviral ENV protein, comprises one of the amino acid sequences selected from the group consisting of SEQ ID NO: 96-211.
8. The pharmaceutical composition according to claim 1 , wherein said isolated mutated human or simian lentiviral ENV protein, or said fragment of said isolated mutated human or simian lentiviral ENV protein, comprises one of the amino acid sequences selected from the group consisting of SEQ ID NO: 212-269.
9. The pharmaceutical composition according to claim 6 , wherein the lentiviral infection is HIV-1 infection, HIV-2 infection or SIV infection.
10. The pharmaceutical composition according to claim 6 , wherein the formulation is capable of inducing an anti-lentiviral immune response against HIV-1 infection, HIV-2 infection or SIV infection.